Plumbline Life Sciences, Inc. (XKON:222670)
5,980.00
-60.00 (-0.99%)
At close: Oct 28, 2025
Plumbline Life Sciences Company Description
Plumbline Life Sciences, Inc. engages in the development and sale of DNA medicines for animals.
Its products include LifeTide SW5, a pig immune-modulator; PLS-ASF, a swine fever DNA vaccine; PLS-FMD; PLS-B3000, a dairy cattle DNA therapy; PLS-IF1000, a FMD vaccine; PLS-H1000, a horse laminitis therapy; PLS-D5000, a dog DNA cancer immunotherapy; PLS-D1000 for age related immune deficiency in senior dogs; and PLS-C2000 for age related immune deficiency in senior cats.
Plumbline Life Sciences, Inc. was founded in 2014 and is headquartered in Seoul, South Korea.
Plumbline Life Sciences, Inc.
| Country | South Korea |
| Founded | 2014 |
| Industry | Biological Products, Except Diagnostic Substances |
| CEO | Anthony K. Kim |
Contact Details
Address: 18, Seocho-daero 34-gil Seoul, 06661 South Korea | |
| Phone | 82 2 582 3540 |
| Website | plumblinels.com |
Stock Details
| Ticker Symbol | 222670 |
| Exchange | Korea New Exchange |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Anthony K. Kim | Chief Executive Officer |
| Youngki Lee | Chief Financial Officer |